TNFSF13B
ENSG00000102524
Target class
Secreted protein
Chromosome
13
Approved drugs
1
Clinical candidates (approved and in development)
7
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- No
- Target name
- TNFSF13B
- Gene name
- TNF superfamily member 13b
- Gene symbol
- TNFSF13B
- Previous gene symbols
- TNFSF20
- Protein name
- Tumor necrosis factor ligand superfamily member 13B (B lymphocyte stimulator) (BLyS) (B-cell-activating factor) (BAFF) (Dendritic cell-derived TNF-like molecule) (TNF- and APOL-related leukocyte expressed ligand 1) (TALL-1) (CD antigen CD257) [Cleaved into: Tumor necrosis factor ligand superfamily member 13b, membrane form; Tumor necrosis factor ligand superfamily member 13b, soluble form]
- BAFF
- THANK
- BLYS
- TALL-1
- TALL1
- CD257
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Tumor necrosis factor superfamily
- Target class
- Secreted protein
- Target type
- Human gene
- Tissues expressed in
- 49
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 35.02
- Tissue specificity (Gini)
- 0.517
- Tissue specificity (tau)
- 0.922
- KEGG gene identifiers
- hsa:10673
- Protein interaction confidence
- 0.816732
- Protein interaction partners
- 41
- R-HSA-5668541
- R-HSA-5669034
- R-HSA-5676594
- End position
- 108308484
- Start position
- 108251240
- Chromosome
- 13
- Strand
- Forward
- Cell membrane
- Single-pass type II membrane protein.
- SUBCELLULAR LOCATION: [Tumor necrosis factor ligand superfamily member 13b, soluble form]: Secreted.
- Focal adhesion sites
- Plasma membrane
- Vesicles
- Tissue specificity (tau)
- 0.921705
- Expression inequality (Gini)
- 0.516765
Expression in transcripts per million
- Whole Blood
- 35.02
- Lung
- 14.48
- Cells - EBV-transformed lymphocytes
- 13.06
- Spleen
- 11.94
- Adipose - Visceral (Omentum)
- 6.02
Expression in transcripts per million
- Whole Blood35.02
- Lung14.48
- Cells - EBV-transformed lymphocytes13.06
- Spleen11.94
- Adipose - Visceral (Omentum)6.02
- Artery - Coronary5.97
- Adrenal Gland5.43
- Thyroid5.07
- Small Intestine - Terminal Ileum3.95
- Artery - Aorta3.6
- Brain - Spinal cord (cervical c-1)3.44
- Adipose - Subcutaneous3.07
- Nerve - Tibial2.97
- Breast - Mammary Tissue2.64
- Bladder2.61
- Vagina2.54
- Artery - Tibial2.53
- Heart - Atrial Appendage2.48
- Prostate2.37
- Cervix - Ectocervix2.34
- Brain - Frontal Cortex (BA9)2.2
- Minor Salivary Gland2.2
- Cervix - Endocervix2.13
- Esophagus - Gastroesophageal Junction2.12
- Fallopian Tube2.12
And 29 more, listed on the interactive page.
- GO:0007165
- GO:0030890
- GO:0005576
- GO:0005737
- GO:0005886
- GO:0048471
- GO:0005102
- GO:0005515
Related records
Trials (151)
- A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
- A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States
- A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01
- A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02
- A Model About the Response of Belimumab in SLE
- A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
- A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib
- A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
- A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)
- A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies
- A Rheumatoid Arthritis Study in Participants
- A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methotrexate
- A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept
- A Safety and Efficacy Study of LymphoStat-B™ (Monoclonal Anti-BLyS Antibody) in Subjects With Rheumatoid Arthritis (RA)
- A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
- A Study for Japanese Participants With Rheumatoid Arthritis (RA)
- A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
- A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy
- A Study in Participants With End-Stage Renal Disease
- A Study in Participants With Rheumatoid Arthritis
Drugs (7)
- Atacicept Tumor necrosis factor ligand superfamily member 13B inhibitor
- Belimumab Tumor necrosis factor ligand superfamily member 13B inhibitor
- Blisibimod Tumor necrosis factor ligand superfamily member 13B inhibitor
- Briobacept Tumor necrosis factor ligand superfamily member 13B inhibitor
- Rozibafusp alfa Tumor necrosis factor ligand superfamily member 13B inhibitor
- Tabalumab Tumor necrosis factor ligand superfamily member 13B inhibitor
- Tibulizumab Tumor necrosis factor ligand superfamily member 13B inhibitor